ReviewFrontiers in oncology2026
Integrative precision oncology in neuroblastoma: multi-omics biomarkers, molecular targets, and immunotherapeutic strategies.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma is the most frequent extracranial solid tumor of young children and demonstrates a wide range of biological behavior, from spontaneous regression to highly aggressive metastatic disease. Recent advances in genomics, epigenetics, tumor microenvironment biology, and multi-omics technologies have greatly enhanced understanding of neuroblastoma pathogenesis and enabled the development of precision diagnostic and prognostic approaches. This review examines current evidence for molecular and cellular mechanisms underlying neuroblastoma initiation, progression, and therapeutic resistance, with a focus on MYCN amplification, ALK pathway dysregulation, chromosomal instability, telomere maintenance mechanisms, epigenetic remodeling, and neural crest developmental biology. This review primarily emphasizes that these characteristics should be interpreted within a unified developmental framework. In this context, age serves more as an indicator of the differentiation status of the sympathoadrenal progenitor pool rather than merely a timeline for the accumulation of somatic mutations. This viewpoint connects the epigenetic, genetic, and clinical aspects of the disease, providing insight into its distinctive range of behaviors, from spontaneous regression in infants to fatal progression in older children. The promising role of integrative diagnostic platforms - such as genomic profiling, liquid biopsy, radiomics, metabolomics, single-cell sequencing, and artificial intelligence-aided imaging approaches - in early detection and disease characterization is explored in detail. The evaluation of both existing and emerging prognostic models involves a critical analysis of molecular biomarkers, tumor microenvironment signatures, circulating tumor DNA, immune profiling, and machine-learning-based stratification systems. Additionally, the translational potential of systems biology approaches is examined, along with future directions for integrating multi-omics data into clinically relevant precision oncology frameworks. Integrative approaches are collectively reshaping neuroblastoma research by connecting molecular pathogenesis with advanced diagnostic and prognostic tools. These developments are expected to facilitate enhanced risk-adapted therapeutic strategies, personalized medicine, and ultimately, improved survival rates in children with neuroblastoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.